TERF1 and gastric cancer: The upregulated tRF-+1:T17-Glu-TTC-2-2 inhibits the MAPK signaling pathway by downregulating the expression of ERK1/2, JNK and p38, thus significantly inhibiting the proliferation, migration and invasion of GC cells both in vitro and in vivo (58).